[go: up one dir, main page]

ECSP14013264A - Nuevos derivados bicíclicos de dihidroquinolina-2-ona - Google Patents

Nuevos derivados bicíclicos de dihidroquinolina-2-ona

Info

Publication number
ECSP14013264A
ECSP14013264A ECSP14013264A ECSP14013264A EC SP14013264 A ECSP14013264 A EC SP14013264A EC SP14013264 A ECSP14013264 A EC SP14013264A EC SP14013264 A ECSP14013264 A EC SP14013264A
Authority
EC
Ecuador
Prior art keywords
dihidroquinolina
ona
bicyclic derivatives
new bicyclic
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
Peter Mohr
Kurt Amrein
Alexander V Mayweg
Hans Peter Maerki
Aurel Johannes Aebi
Benoit Hornsperger
Bernd Kuhn
Serena Maria Fantasia
Yongfu Liu
Michelangelo Scalone
Xuefei Tan
Mingwei Zhou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013264(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP14013264A publication Critical patent/ECSP14013264A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona nuevos compuestos que poseen la fórmula general (I) (I)en el que R1, R2, R3, R4¸ R5, R6, R7, R8, R9, R10, R11, R12, A1, A2 A3 y n son tal como se ha descrito aquí, las composiciones que incluyen los compuestos y los métodos para utilizar los compuestos.
ECSP14013264 2011-09-23 2014-03-21 Nuevos derivados bicíclicos de dihidroquinolina-2-ona ECSP14013264A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011080078 2011-09-23

Publications (1)

Publication Number Publication Date
ECSP14013264A true ECSP14013264A (es) 2014-04-30

Family

ID=46963698

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013264 ECSP14013264A (es) 2011-09-23 2014-03-21 Nuevos derivados bicíclicos de dihidroquinolina-2-ona

Country Status (34)

Country Link
US (1) US9353081B2 (es)
EP (1) EP2758388B1 (es)
JP (1) JP6012737B2 (es)
KR (1) KR101723276B1 (es)
CN (1) CN103827101B (es)
AR (1) AR087984A1 (es)
AU (1) AU2012311582B2 (es)
BR (1) BR112014006660B1 (es)
CA (1) CA2845170C (es)
CL (1) CL2014000663A1 (es)
CO (1) CO6870035A2 (es)
CR (1) CR20140089A (es)
DK (1) DK2758388T3 (es)
EA (1) EA035108B1 (es)
EC (1) ECSP14013264A (es)
ES (1) ES2666802T3 (es)
HR (1) HRP20180592T1 (es)
HU (1) HUE038773T2 (es)
IL (1) IL230874A (es)
LT (1) LT2758388T (es)
MX (1) MX366095B (es)
MY (1) MY186165A (es)
NO (1) NO2758388T3 (es)
PE (2) PE20181378A1 (es)
PH (1) PH12014500584A1 (es)
PL (1) PL2758388T3 (es)
PT (1) PT2758388T (es)
RS (1) RS57139B1 (es)
SG (1) SG2014010599A (es)
SI (1) SI2758388T1 (es)
TW (1) TWI576342B (es)
UA (1) UA115972C2 (es)
WO (1) WO2013041591A1 (es)
ZA (1) ZA201401577B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
SI2838883T1 (en) * 2012-04-17 2018-02-28 F. Hoffmann-La Roche Ag New derivatives of phenyl-tetrahydroisoquinoline
WO2014076162A1 (en) 2012-11-19 2014-05-22 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines
CA2898349A1 (en) * 2013-03-14 2014-09-18 F. Hoffmann-La Roche Ag Dihydroquinoline-2-one derivatives for use as aldosterone synthase inhibitors
EP3004076B1 (en) * 2013-05-27 2019-10-23 F.Hoffmann-La Roche Ag New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
JP6581970B2 (ja) * 2013-05-27 2019-09-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規3,4−ジヒドロ−2h−イソキノリン−1−オン及び2,3−ジヒドロ−イソインドール−1−オン化合物
ES2763338T3 (es) * 2013-05-27 2020-05-28 Hoffmann La Roche Nuevos compuestos de 3,4-dihidro-2H-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona
CA2915788A1 (en) * 2013-10-17 2015-04-23 F. Hoffmann-La Roche Ag New phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors
EP3057940A1 (en) 2013-10-17 2016-08-24 F.Hoffmann-La Roche Ag Phenyl-dihydropyridine derivatives as inhibitors of aldosterone synthase
CN105593212B (zh) * 2013-10-17 2019-06-04 豪夫迈·罗氏有限公司 作为醛固酮合酶抑制剂的苯基-二氢吡啶衍生物
JP6669734B2 (ja) * 2014-10-31 2020-03-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ピラゾリル−3,4−ジドヒドロキノリン−2−オン・アルドステロン合成酵素阻害剤
WO2016066597A1 (en) * 2014-10-31 2016-05-06 F. Hoffmann-La Roche Ag New dihydroquinoline pyrazolyl compounds
CN106604917B (zh) * 2014-10-31 2020-10-09 豪夫迈·罗氏有限公司 作为醛固酮合酶抑制剂的新型二氢喹啉吡唑基化合物
US9890171B2 (en) 2014-12-02 2018-02-13 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
CA3026617A1 (en) * 2016-06-10 2017-12-14 Nihon Medi-Physics Co., Ltd. Non-invasive diagnostic imaging agent for heart disease
US11958818B2 (en) 2019-05-01 2024-04-16 Boehringer Ingelheim International Gmbh (R)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
JP2024523559A (ja) * 2021-06-24 2024-06-28 シンコア・ファーマ・インコーポレイテッド アルドステロン合成酵素阻害剤を使用する方法
WO2023063851A1 (en) * 2021-10-13 2023-04-20 «Target Medicals» Limited Liability Company Inhibitors of human aldosterone synthase (cyp11b2)
KR20240122521A (ko) 2021-12-14 2024-08-12 베링거 인겔하임 인터내셔날 게엠베하 만성 신장 질환 치료용 알도스테론 신타아제 억제제
EP4580630A1 (en) 2022-09-02 2025-07-09 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
CN119894905A (zh) * 2022-09-23 2025-04-25 广州威诺森医药科技有限公司 一种骈环吡啶类甾体合成酶抑制剂及其制备方法和应用
EP4624464A1 (en) * 2022-11-23 2025-10-01 Shanghai Hansoh Biomedical Co., Ltd. Pyridine polycyclic compound inhibitor, preparation method therefor and use thereof
WO2024222814A1 (zh) * 2023-04-28 2024-10-31 长春金赛药业有限责任公司 Cyp11b2抑制剂化合物、药物组合物及其应用
WO2024235165A1 (zh) * 2023-05-12 2024-11-21 南京明德新药研发有限公司 含氮杂环类化合物及其应用
AU2024310688A1 (en) * 2023-06-29 2026-01-29 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of baxdrostat, and preparation method therefor and use thereof
WO2025021062A1 (zh) * 2023-07-21 2025-01-30 上海翰森生物医药科技有限公司 三并环类化合物、及其制备方法和应用
WO2025054172A1 (en) 2023-09-05 2025-03-13 E-Star Biotech, LLC Formulations of manp and uses thereof
CN117247371A (zh) * 2023-09-18 2023-12-19 上海相辉医药科技有限公司 一种cyp11b2抑制剂baxdrostat的制备方法
TW202519227A (zh) * 2023-11-10 2025-05-16 大陸商上海齊魯製藥研究中心有限公司 稠環衍生物、其製備方法及其在醫藥上的應用
WO2025125513A1 (en) 2023-12-15 2025-06-19 AstraZeneca Ireland Limited Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension
CN120289471B (zh) * 2024-03-01 2025-10-17 浙江扬厉医药技术有限公司 吡喃并吡啶类化合物、其制备方法、药物组合物及应用
WO2025256482A1 (zh) * 2024-06-12 2025-12-18 江苏德源药业股份有限公司 一种吡啶并环类化合物及其制备和应用
WO2025261526A1 (zh) * 2024-06-21 2025-12-26 上海翰森生物医药科技有限公司 双稠环类化合物、及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792561A (en) * 1986-05-29 1988-12-20 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors
GB8709448D0 (en) * 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
WO2005065050A2 (ja) * 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation 2環化合物
JP5202327B2 (ja) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2

Also Published As

Publication number Publication date
ZA201401577B (en) 2015-01-28
TWI576342B (zh) 2017-04-01
JP6012737B2 (ja) 2016-10-25
CL2014000663A1 (es) 2014-10-03
WO2013041591A1 (en) 2013-03-28
AU2012311582B2 (en) 2017-07-06
KR20140076591A (ko) 2014-06-20
BR112014006660B1 (pt) 2021-08-17
SG2014010599A (en) 2014-04-28
EP2758388B1 (en) 2018-02-21
HRP20180592T1 (hr) 2018-05-18
HUE038773T2 (hu) 2018-11-28
MX366095B (es) 2019-06-27
PE20141042A1 (es) 2014-08-27
NO2758388T3 (es) 2018-07-21
ES2666802T3 (es) 2018-05-07
UA115972C2 (uk) 2018-01-25
PH12014500584A1 (en) 2017-04-26
MY186165A (en) 2021-06-30
EA035108B1 (ru) 2020-04-28
SI2758388T1 (en) 2018-05-31
RS57139B1 (sr) 2018-07-31
US20130079365A1 (en) 2013-03-28
KR101723276B1 (ko) 2017-04-04
DK2758388T3 (en) 2018-05-07
CA2845170C (en) 2019-08-13
CO6870035A2 (es) 2014-02-20
PT2758388T (pt) 2018-04-17
NZ620652A (en) 2016-09-30
AU2012311582A1 (en) 2014-02-20
CR20140089A (es) 2014-03-21
AR087984A1 (es) 2014-04-30
CN103827101B (zh) 2016-12-07
BR112014006660A2 (pt) 2017-04-04
JP2014526539A (ja) 2014-10-06
MX2014002624A (es) 2014-04-14
PL2758388T3 (pl) 2018-08-31
IL230874A (en) 2016-07-31
EA201490567A1 (ru) 2014-07-30
EP2758388A1 (en) 2014-07-30
CA2845170A1 (en) 2013-03-28
IL230874A0 (en) 2014-03-31
TW201319054A (zh) 2013-05-16
CN103827101A (zh) 2014-05-28
PE20181378A1 (es) 2018-09-05
LT2758388T (lt) 2018-05-10
US9353081B2 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
ECSP14013264A (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
CU24309B1 (es) Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen
MX2017004541A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa.
CL2017002452A1 (es) Nuevos compuestos bicíclicos
SV2018005791A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CU20170164A7 (es) Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen
SV2017005590A (es) Nuevos derivados hidroxiacido un proceso para su preparacion y composiciones farmaceuticas que los contienen
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
UY36734A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20170573A (es) Lactamas bicíclicas y métodos de uso de las mismas
CR20140135A (es) Nuevos derivados de aril-quinolina
CR20140275A (es) Triazolopiridinas sustituidas
CR20140548A (es) Derivados de aril-sultamo como moduladores de rorc
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
ECSP14013215A (es) Compuestos novedosos
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
MX343225B (es) Nuevos derivados de aril-benzocicloalquil-amida.
ECSP17069696A (es) Compuestos novedosos
BR112014030474A2 (pt) novos compostos bicíclicos de tiofenilamida
CU20160010A7 (es) NUEVOS COMPUESTOS ISOINDOLlNA O ISOQUINOLlNA ÚTILES COMO INHIBIDORES ANTIAPOPTÓTICOS Bcl-2 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CR20150148A (es) Azaindolinas